Orchard Therapeutics Plc (ORTX) Tops Q4 EPS by 147c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Orchard Therapeutics Reports 2018 Financial Results and Reviews Recent Business Highlights
March 21, 2019 7:01 AM EDTThree Lead Programs for MLD, ADA-SCID and WAS on Track for Regulatory Filings Over the Next Three Years, with MLD and ADA-SCID Expected in 2020
Registrational Data Showing 100% Overall Survival and 100% Event-Free Survival at Two Years in ADA-SCID Patients Recently Presented at ASBMT; Two and Three Year Data in MLD Patients to be Presented Next Week at EBMT
Recent CTO Appointment Enhances Global Commercial Manufacturing Capabilities
Strong Financial Position with Approximately $340M in Total Cash and Investments
BOSTONandLONDON, March 21, 2019 (GLOBE NEWSWIRE) -- Orchard... More
